Apollo Hospitals has announced a strategic collaboration with Ainnova Tech, a healthcare technology company, to integrate artificial intelligence (AI) into disease detection and prediction.
This partnership has led to Ainnova securing an exclusive license for advanced AI algorithms, validated with more than 2.3 million data points, for its Vision AI platform.
Go deeper with GlobalData
These AI solutions are designed to enhance the early and precise detection of various conditions, including liver fibrosis, cardiovascular and chronic kidney diseases, type 2 diabetes, and lung abnormalities.
Last month, Avant Technologies and Ainnova formed a joint venture, Ai-Nova Acquisition (AAC), and signed a global development and licensing deal.
With AAC now holding a global licence to develop and market Ainnova’s technology, the collaboration with Apollo strengthens the venture’s global efforts to advance AI in healthcare.
These AI-driven diagnostics are set to be available on the Vision AI platform across the Americas, with the first commercial pilot programmes launching soon.
With a population of over 200 million, Brazil is set to expand, having met the regulatory requirements of Brazil’s Health Regulatory Agency, ANVISA.
Integrating the AI-powered solution aims to enhance chronic disease management by adding value to patient care.
These tools offer a comprehensive preventive health assessment and will enable early referrals from primary care or community health services to specialised medical professionals.
Apollo and Ainnova aim to further develop and deploy AI-driven healthcare solutions, with additional innovations expected to be introduced shortly.
Earlier this month, Apollo Hospitals signed a term sheet with Ion Beam Applications (IBA) for the procurement of one ProteusONE compact proton therapy solution.
